PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hippokratiaLink to Publisher's site
 
Hippokratia. 2006 Jul-Sep; 10(3): 105–111.
PMCID: PMC2808392

Late pregnancy complications in polycystic ovarian syndrome

Abstract

Gestational diabetes mellitus and new-onset hypertension, which includes gestational hypertension and pre-eclampsia, are common complications of pregnancy. Many features of the insulin resistance syndrome have been associated with these conditions. These include glucose intolerance, hyperinsulinemia, hypertension, obesity, and lipid abnormalities. Other accompanying abnormalities may include elevated serum levels of leptin, TNFα, plasminogen activator inhibitor-1 and testosterone. The establishment of these features before the onset of gestational diabetes mellitus and hypertension in pregnancy suggests that insulin resistance or associated abnormalities may play a role in these disorders. These observations suggest that therapeutic interventions to reduce insulin resistance may lower the risk of both gestational diabetes mellitus and hypertension in pregnancy.

Keywords: pregnancy, insulin resistance, gestational diabetes mellitus, hypertension in pregnancy, pre-eclampsia

Introduction

With a prevalence of 5%-10% the polycystic ovary syndrome (PCOS) is probably the most common endocrine abnormality in women of reproductive age14. Besides reproductive endocrine abnormalities, including amenorrhea or oligomenorrhea, hyperandrogenism and chronic anovulation, a key feature of PCOS is insulin resistance (nearly 80% of obese and 30% of lean women with PCOS demonstrate insulin resistance) with compensatory hyperinsulinemia and a β-cell dysfunction5,6.

The presence of insulin resistance in PCOS has important later consequences upon health. Insulin resistance is associated with an increased risk for several disorders, including type 2 diabetes, hypertension, dyslipidaemia, endothelial dysfunction, elevated endothelin-1 and cardiovascular disease. This group of abnormalities coupled with insulin resistance constitutes the so-called "metabolic syndrome"7. Many women with PCOS show a phenotype similar to Syndrome X. Therefore, PCOS may be considered a component of the metabolic syndrome8.

It has been demonstrated that women with PCOS present an increased risk for diabetes development and hypertension during pregnancy918. These complications might be attributed to the coexisted insulin resistance and β-cell dysfunction in a significant percentage of women with PCOS before conception5,6.

Insulin resistance of normal pregnancy

Pregnancy is a complex metabolic entity that involves major alterations in the hormonal status as well as an increasing burden of fuel utilisation by the conceptus. In normal pregnancy, insulin resistance and compensatory hyperinsulinemia occur in the second and maximize in the third trimester of pregnancy. The insulin resistance of normal pregnancy is advantageous. It is regulated by placental hormones and is a physiological adaptation that ensures adequate amounts of maternal glucose to the increasing nutritional and growth demands of the developing fetus17, 1922

The insulin resistance of normal pregnancy is probably mediated by several hormonal changes, including increases in serum levels of estradiol, progesterone, prolactin, cortisol, human chorionic gonadotropin, placental growth hormone and human placental lactogen. Human placental lactogen (hPL) has been considered as the main insulin resistance hormone of pregnancy23. Human placental lactogen presents its peak at thirty weeks of gestation and has been shown to have both insulin and anti-insulin effects. The major role of hPL may be the adaptive increase in insulin secretion necessary for pregnancy rather than the induction of insulin resistance. Tumour necrosis factor-alpha (TNF-α) was recently demonstrated to have a strong correlation with the insulin resistance of pregnancy but its role is not yet clear24.

Human placental growth hormone (hPGH) is probably the main factor to mediate the insulin resistance of pregnancy, since it is known that chronically elevated levels of pituitary growth hormone have diabetogenic effects. Human placental growth hormone differs from pituitary growth hormone by 13 amino-acids25. It is not regulated by growth hormone releasing hormone (GHRH) or inhibited by somatostatin analogues, but has the same affinity for the GH receptor as the pituitary growth hormone. By twenty weeks of gestation it replaces pituitary GH almost completely in the maternal circulation. Human placental GH does not cross the placenta and appears to regulate the maternal levels of IGF-1. Maternal IGF-1 levels in plasma correlate with hPGH levels, not with hPL. Human placental growth hormone seems to be a paracrine growth factor, which through insulin growth factors may partially regulate the metabolic, and growth needs of the fetus. Barbour et al recently demonstrated in transgenic mice that hPGH, at levels similar to the third trimester of human pregnancy, causes severe insulin resistance, exhibited by both fasting and post-prandial hyperinsulinaemia; these mice require insulin levels that are five to seven times higher in order to maintain euglycaemia. They also demonstrate a marked decrease in insulin-induced GLUT-4 translocation to the plasma membrane. Additionally, Barbour et al found that the skeletal muscle tissue of these mice demonstrate abnormalities in insulin signaling which bear a remarkable similarity to that found in normal pregnant women and in pregnant women with gestational diabetes. These data suggest that human placental growth hormone may be a significant mediator of insulin resistance in normal pregnancy26,27.

The insulin resistance of normal pregnancy has been well described. Nevertheless, the hormonal mechanisms by which insulin resistance is triggered remain a subject of debate. Normal pregnancy is characterized by a '50% decrease in insulin-mediated glucose disposal and by a 200%-250% increase in insulin secretion in humans20,28. Hepatic gluconeogenesis is not normally suppressed by insulin. This procedure occurs in order to meet the metabolic demands of the fetus, of which glucose represents a 80% of the fetal energy, yet it maintains euglycaemia in the mother29. In normal pregnancy there is a decreased expression of the GLUT-4 glucose transporter protein in maternal adipose tissue30 but not in skeletal muscle. Skeletal muscle is the main site of insulin-mediated glucose disposal in vivo, suggesting that the mechanisms behind insulin resistance in skeletal muscle lie or in the pathways for insulin signaling or in the abnormal translocation of GLUT-4 31.

It has been demonstrated that in human incubated muscle fibres obtained at term by caesarean section from normal pregnant women with obesity, maximal insulin-stimulated 2-deoxyglucose transport was significantly reduced by 32% 31. In these skeletal muscle fibres, normal pregnancy caused reduced insulin receptor tyrosine kinase activity toward IRS-1 as well as reduced expression of insulin receptor substrate-1 (IRS-1)32. Recent data in pregnancy also demonstrate increases in serine phosphorylation of the insulin receptor, which may prevent optimal binding of IRS-1 to phosphotidylinositol (PI) 3-kinase resulting in inhibition of GLUT-4 translocation32.

Insulin resistance in gestational diabetes

In pregnancies complicated by gestational diabetes mellitus (GDM) further insulin resistance occurs and an inability to a compensatory increase in insulin secretion appears20,28,33. The pancreatic beta cell secretory defect is present in both obese and lean women with GDM. It has been demonstrated that overweight women who will develop GDM present insulin resistance prior to pregnancy as measured by a hyperinsulinaemiceuglycaemic clamp20. Insulin-mediated glucose disposal continues to decrease in the second and third trimester of pregnancy and is about two-thirds that of normal pregnant women matched for weight. Moreover, women with GDM improve their insulin resistance postpartum; however, they never achieve the same degree of insulin-mediated glucose disposal as normal pregnant women do.

Studies on muscle fibres from pregnant women undergoing caesarean section demonstrated that the mechanisms for skeletal insulin resistance in obese women with GEM involve impaired insulin receptor β-subunit tyrosine-phosphorylation and decreased IRS-1-phosphorylation and expression31,32. A significant decrease in maximal insulin receptor tyrosine-phosphorylation was demonstrated in muscle from obese GDM women compared to obese pregnant women30,31. This insulin receptor tyrosine kinase activity (IRTK) catalyses the phosphorylation of various insulin receptor substrates, particularly IRS-1, to undergo tyrosine-phosphorylation. While insulin receptor tyrosine-phosphorylation is impaired in GDM patients only, IRTK is significantly reduced by 23% in pregnancy and by 41% in the muscle fibres of GDM patients compared to obese non-pregnant controls. Conclusively, these data suggest a possible insulin receptor defect that may exacerbate the physiological effects of normal pregnancy.

Gestational diabetes mellitus in women with polycystic ovary syndrome

Gestational diabetes mellitus is detected in 3%-4% of pregnancies in women aged 15-49 years and is associated with an increased later risk for type 2 diabetes. Risk factors for gestational diabetes include obesity, age, genetic background, PCOS and ethnicity34. Fetal macrosomia in gestational diabetes increases the rates of birth trauma and cesarean section35. Diagnosis and management of gestational diabetes may reduce perinatal, neonatal, and long-term pediatric complications34,35.

Insulin resistance and hyperinsulinemia all of which are risk factors for gestational diabetes characterize women with PCOS. These women, 46% of whom develop GDM36, enter pregnancy with higher insulin resistance than normal women3641. Women with PCOS probably develop GDM when pancreatic?-cells cannot overcome the superimposition of the physiological insulin resistance of pregnancy on their high preconception insulin resistance 914,36. Women in whom gestational diabetes develops are likely to have underlying polycystic ovaries42 and women with PCOS are likely to develop gestational diabetes5,9,10,39.

Obesity, which characterizes a great percentage of PCOS patients, has a deleterious additive effect on carbohydrate homeostasis and increases insulin resistance during gestation43. In normal women, high maternal insulin in early pregnancy promotes gestational weight gain and weight retention post-partum, increasing the risk of GDM and, later of type 2 diabetes mellitus 44. Body mass index (BMI) >25 kg/m2 is a major predictor of GDM45.

Women with polycystic ovary syndrome often present with infertility 46,47. Therefore, women with PCOS are older than the general population at conception, which is another risk factor for gestational diabetes15.

The association among insulin resistance, metabolic syndrome, and androgen excess in PCOS has led to the use of insulin-sensitizing agent such as metformin with reported improvements in hyperinsulinemia and hyperandrogenemia. Treatment with metformin only, produced a modest reduction in weight and hirsutism in women with PCOS48. Metformin administration throughout pregnancy in women with PCOS reduces GDM, from 26%-31% to 3%-4% 13,49,50. Thus, the frequency of GDM in women with PCOS on metformin does not differ from normal pregnant controls15.

Metformin administration during pregnancy leads to a modification of the observed changes in insulin resistance during gestation. In women on metformin, serum insulin levels did not rise significantly during the first and the second trimesters of pregnancy compared to the last preconception visit. Moreover, on metformin there was no difference in fasting serum insulin levels between the third trimester (increase only 10%) and the last preconception visit on metformin, with insulin levels also lower in the third trimester than before metformin initiation17. Consequently, the expected changes during pregnancy, namely a significant increase in insulin and insulin resistance, were abated and blunted, by metformin, suggesting that metformin improves the "natural" insulin resistance changes during gestation in hyperinsulinemic PCOS women10,17, 19,20,36.

A second benefit of metformin treatment in women with PCOS is weight maintenance before conception and weight loss throughout pregnancy, particularly evident in women with BMI 30-40 and 340Kg/m2. These actions probably contribute to insulin resistance reduction and to the development of GDM1114.

A third effect of metformin treatment during pregnancy in women with PCOS is serum testosterone lowering, which, like the prevention of weight gain, is probably mediated through its insulin sensitizing action51,52. It has been proposed that high androgen levels during pregnancy in untreated women with PCOS could provide a potential source of androgen excess for the fetus, without leading to fetal virilization53. Metformin treatment throughout pregnancy in PCOS should reduce any putative risk of fetal virilization conferred through androgen excess17.

Hypertensive disorders of pregnancy (HDP)

A percentage of 5%–10% of pregnancies are complicated by pregnancy-induced hypertension. This disorder is a major cause of maternal, fetal, and neonatal morbidity and mortality. Although complications of hypertensive disorders of pregnancy (HDP) have been recognized for centuries, the causes of these disorders remain poorly understood. Various data indicating associations of features of the insulin resistance syndrome and these disorders suggest that additional research is needed to elucidate the potential role of insulin resistance in the pathogenesis of pregnancy induced hypertension.

Hypertensive disorders of pregnancy include:

  1. new onset of hypertension during pregnancy (gestational hypertension or preeclampsia),
  2. pre-existing hypertension, and
  3. exacerbation of pre-existing hypertension54.

New-onset hypertension develops during the second half of pregnancy, usually in the third trimester in 3%5% of women who were previously normotensive. Preeclampsia is a multi-system syndrome mainly characterized by proteinuria (300 mg protein or more over 24 h). Proteinuria due to glomerular endotheliosis and oedema secondary to increased vascular permeability represent only the "tip of an iceberg" of a widespread pathology arising from endothelial dysfunction and damage18. Other systemic manifestations include generalized intravascular coagulation, haemolysis, elevated liver function tests, and, rarely, seizures (eclampsia). Gestational hypertension, a generally more benign disorder, is diagnosed when blood pressure is elevated in the absence of the above findings. When other systemic manifestations of disease are absent, the distinction between preeclampsia and gestational hypertension is based on the presence and magnitude of proteinuria. It is not clear whether gestational hypertension and preeclampsia are different disease entities or different manifestations of the same disease process. It is possible that insulin resistance may play an important role in both of them. Twenty per cent of women with pre-existing hypertension develop superimposed preeclampsia, with its attendant risks.

The etiology of hypertensive pregnancy is uncertain and includes immune, genetic, and placental abnormalities. Three main hypotheses have been proposed regarding the metabolic alterations involved in the aetiology of hypertensive disorders in pregnancy, namely endothelial dysfunction and activation, oxidative stress and insulin resistance. All may contribute to the characteristic endothelial dysfunction of hypertensive disorders in pregnancy. Endothelial dysfunction may, in turn, underlie several critical features of preeclampsia, including vasoconstriction, hypertension, loss of the usual pregnancy-associated refractoriness to pressor effects of angiotensin II, increased platelet aggregation, and proteinuria54.

It has been postulated that abnormalities of the placenta are the primary cause of preeclampsia. However, the observations that several metabolic abnormalities predispose to the development of preeclampsia, and that these abnormalities are also observed in the non-pregnant state in women who have had preeclampsia, suggest that maternal features must also be considered.

All cases of new onset HDP are unlikelyto be attributable to a single cause. Rather, different etiologies may lead to the same phenotype in different women.

Endothelial dysfunction and activation

Many markers of endothelial dysfunction have been observed in HDP. Coagulation activation proceeds weeks to months the clinical onset. The damaged endothelium of HDP is reflected by elevated levels of plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor18. Endothelial dysfunction is indicated by the elevated plasma levels of soluble adhesion molecules, which may be manifested before the clinical onset55. Although the increased serum levels of cytokines (TNFα, IL-6 and IL-8), observed only in the HDP group, indicated that endothelial activation is a consequence of abnormal trophoblast invasion, still additional factors are involved in its manifestation, which might be related to cytokine release.

Endothelial activation in HDP results in an enormous release of endothelin, thromboxane and superoxide, as well as an increased vascular sensitivity to the pressor effects of angiotensin II, and a decreased formation of vasodilators such as nitric oxide and prostacyclin by the damaged endothelium56. This may lead to an increase in total peripheral resistance, despite the increasing plasma volume of pregnancy, and thus to vasospasm and hypertension. However, a case control study, of non-pregnant, normotensive pregnant and HDP pregnant women, showed that nitric oxide (NO) and endothelin-1 production were increased in the hypertensive disorders in pregnancy group compared to the other groups57. The increased formation of the vasodilator NO was considered to be a compensatory response to the vasoconstriction and hypertension.

Oxidative stress

Oxidative stress is a component of HDP. The oxidative stress theory of HDP involves the hypothesis that the abnormal placentation and dyslipidaemia results in a release of free radicals, particularly superoxide anions, and lipid hydroperoxides, which damage the vascular endothelium 58. Oxidative stress may link the decreased placental perfusion in HDP to the maternal response, via direct vascular damage and endothelial dysfunction.

Data from the literature support the view that antioxidant supplementation was associated with an improvement in biochemical indices of the disease. Evidently, these findings need further investigation via large randomised controlled trials, but raise the exciting possibility that antioxidants, either dietary or pharmaceutical, may have a role in the prevention of HDP in high-risk patients. It has been hypothesised that regular exercise enhances antioxidant enzymes in pregnant women, reduces oxidative stress and the incidence of HDP, and at the same time promotes a healthy lifestyle59.

Insulin resistance

In women with HDP an exaggeration of insulin resistance and associated metabolic changes is noted. Although it is not clear to what extent these factors are pathogenic in hypertensive pregnancy, the available data suggest that some may play a rolein the evolution of the disease, whereas others may be markers of the underlying disease process. Exaggerated hyperinsulinemia relative to normalpregnancy is well described in women with established gestational hypertension or preeclampsia. Studies upon insulin resistance have suggested differencesbetween women with de novo hypertension in pregnancy and normotensive women as well.

Insulin resistance precedes the development of HDP. Various studies have documented hyperinsulinemia and/ or hyperglycemia in early or midpregnancy, before the development of preeclampsia, gestational hypertension, or both60,61. Hyperinsulinemia may directly predispose to hypertension by increased renal sodium reabsorption and stimulation of the sympathetic nervous system62. Insulin resistance and/or associated hyperglycemia may impair endothelial function63.

Two other factors, obesity and physical inactivity, are closely associated with insulin resistance, and are predictive of hypertensive pregnancy. A higher body mass index before pregnancy or early in pregnancy is associated with increased risk for both gestational hypertension and preeclampsia60,64,65. Moreover,increased gestational weight gain has also predicted risk for gestational hypertension64 or preeclampsia60, between 6 and 16 weeks. Additional factors, such as dietcomposition, may explain the association between gestational hypertension and gestational weight gain. Furthermore, it has been suggested that gestationaldiabetes, which itself is associated with underlying insulin resistance, is a risk factor for the development of hypertensive pregnancy. This association persists even after adjusting for obesity and maternal age66.

Other putative factors associated\ with hypertensive disorders in pregnancy Lipids

In women with established preeclampsia, serum triglyceride and free fatty acid levels have been found to be higher and high-density lipoprotein cholesterol levels lower than those in women with normotensive pregnancy 67. Elevated total serum cholesterol, triglyceride and free fatty acid levels have been reported to antedate the development of either gestational hypertension or preeclampsia68. Oxidized lipids may impair endothelial function directly or indirectly by effects on prostaglandins, including increased synthesis of thromboxane and inhibited synthesis of prostacyclin69. Increases in small dense LDL and triglycerides may also contribute to impaired endothelial function.

Leptin

It has been reported that leptin levels as early as 20 weeks. gestation may predict the development of preeclampsia in a population of high risk68. Increased leptin levels may in part reflect maternal adiposity and have also been hypothesized to reflect placental insufficiency. Leptin might also contribute to endothelial dysfunction by increasing free fatty acid oxidation70.

TNFα

It has been referred that TNFα or its receptor are elevated in women with established preeclampsia compared with normotensive controls71. Elevated TNFα levels in the early third trimester may predict the development of preeclampsia72. TNFα may promote hypercoagulability and increased lipolysis, with resulting impairment of endothelial relaxation.

PAI-1

PAI-1 is elevatedin established preeclampsia and its increase is related to the severity of the disease. Among women at high risk for preeclampsia, the ratio of PAI-1 to PAI-2, the latter primarily produced by the placenta, was increased before the development of the disease. Increased PAI-1 may reflect impaired fibrinolytic function, which might predispose to the coagulopathy associated with preeclampsia68.

Testosterone and SHBG

Total and free testosterone serum levels are higher in women with established preeclampsia compared with normotensive women. In the first trimester,lower SHBG but neither total nor free testosterone serum levels predicted the later development of preeclampsia73.

Polycystic ovary syndrome, which is associated with insulin resistance, elevated testosterone, and low SHBG levels, has been linked to increased risk for pregnancy-induced hypertension even in the absence of associated obesity74. Androgens increase vasoconstriction in response to pressors75. Androgens also affect the prostaglandin balance, decreasing the synthesis of prostacyclin76, and leading to increased platelet aggregation, which are both characteristics of preeclampsia.

Clinical implications and future directions

Although a cause and effect relationship between the insulin resistance syndrome and gestational diabetes mellitus and new-onset hypertension in pregnancy has not been proven, the associations between these conditions raise the possibility that interventions which improve insulin sensitivity may reduce the likelihood of these pregnancy complications. Because obesity is both a major contributor to insulin resistance and a well established risk factor for preeclampsia, interventions which are scheduled to reduce weight before pregnancy and/or to avoid excessive weight gain during pregnancy may be proved effective. Moreover, increased exercise, which improves insulin sensitivity, may also reduce risk. Given the well-recognized adverse effects of obesity on many pregnancy outcomes, including gestational diabetes and pregnancy-induced hypertension, these approaches might be worthy in women at high risk of these complications. Studies of pharmacological interventions, such as the use of metformin, may also warrant study in women at high risk for preeclampsia.

Multiple studies have demonstrated associations between markers of insulin resistance on one hand and gestational diabetes mellitus and hypertensive pregnancy on the other. Findings consistent with the insulin resistance syndrome have been observed before, during, and after these pregnancy complications. However, further work is needed in several areas. More data are needed to determine whether insulin resistance plays a causal role inthe development of gestational diabetes mellitus, gestational hypertension, and preeclampsia. To improve our ability to identify women at risk for gestational diabetes mellitus and hypertensive pregnancy who might benefit from closer monitoring and intervention, large prospective longitudinal studies are needed to determinewhether there are markers of insulin resistance with sufficient sensitivity and specificity to be clinically relevant. Studies should be designed to assess the effects of specific interventionsdirected to the insulin resistance syndrome on the risk of developing these complications in pregnancy.

References

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011. [PubMed]
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774–800. [PubMed]
3. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 2001;84:1897–1899. [PubMed]
4. Franks S, Gharani N, McCarthy M. Candidate genes in poly¬cystic ovary syndrome. Hum Reprod Update. 2001;47:405–410. [PubMed]
5. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol. 1999;94:194–197. [PubMed]
6. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and β-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86:66–71. [PubMed]
7. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on the detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III) JAMA. 2001;285:2486–2497. [PubMed]
8. Diamanti-Kandarakis E, Baillargeon J-P, Iurno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance and oral contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927–1932. [PubMed]
9. Lanzone A, Caruso A, Di Simone N, De Carolis S, Fulghesu AM, Mancuso S. Polycystic ovary disease. A risk factor for gestational diabetes? J Reprod Med. 1995;40:312–316. [PubMed]
10. Paradisi G, Fulghesu AM, Ferrazzani S, Moretti S, Proto C, Soranna L, Caruso A, Lanzone A. Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy. Hum Reprod. 1998;13:542–54. [PubMed]
11. Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother. 2002;3:1557–1568. [PubMed]
12. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother. 2002;3:1177–1189. [PubMed]
13. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17:2858–2864. [PubMed]
14. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77:520–525. [PubMed]
15. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med. 2004;21:829–836. [PubMed]
16. Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab. 2003;88:2393–2398. [PubMed]
17. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from precon-ception throughout pregnancy. Hum Reprod. 2004;9:510–521. [PubMed]
18. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis. 2004;175:189–202. [PubMed]
19. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and ?-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol. 1990;162:1008–1014. [PubMed]
20. Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999;180:903–916. [PubMed]
21. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care. 2001;24:1602–1607. [PubMed]
22. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr. 2003;133:1674–1683. [PubMed]
23. Handwerger S, Freemark M. The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab. 2000;13:343–356. [PubMed]
24. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, Friedman JE, Kalhan SC, Catalano PM. TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes. 2002;51:2207–2213. [PubMed]
25. Alsat E, Guibourdenche J, Couturier A, Evain-Brion D. Physiological role of human placental growth hormone. Mol Cell Endocrinol. 1998;140:121–127. [PubMed]
26. Barbour LA, Shao J, Qiao L, Pulawa LK, Jensen DR, Bartke A, Garrity M, Draznin B, Friedman JE. Human placental growth hormone causes severe insulin resistance in transgenic mice. Am J Obstet Gynecol. 2002;186:512–517. [PubMed]
27. Barbour LA. New concepts in insulin resistance of pregnancy and gestational diabetes: long-term implications for mother and offspring. J Obstet Gynaecol. 2003;23:545–549. [PubMed]
28. Yamashita H, Shao J, Friedman JE. Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus. Clin Obstet Gynecol. 2000;43:87–98. [PubMed]
29. Aldoretta PW, Hay WW., Jr Metabolic substrates for fetal energy metabolism and growth. Clin Perinatol. 1995;22:15–36. [PubMed]
30. Okuno S, Akazawa S, Yasuhi I, Kawasaki E, Matsumoto K, Yamasaki H, Matsuo H, Yamaguchi Y, Nagataki S. Decreased expression of the GLUT4 glucose transporter protein in adipose tissue during pregnancy. Horm Metab Res. 1995;27:231–234. [PubMed]
31. Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, Catalano P. Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes. 1999;48:1807–1814. [PubMed]
32. Shao J, Catalano PM, Yamashita H, Ruyter I, Smith S, Youngren J. Decreased insulin receptor ty-rosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): evidence for increased serine/threonine phosphorylation in pregnancy and GDM. Diabetes. 2000;49:603–610. [PubMed]
33. Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes Care. 1998;21:B19–B26. [PubMed]
34. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr. 2000;71:S1256–S1261. [PubMed]
35. Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care. 1998;21:B79–B84. [PubMed]
36. Lanzone A, Fulghesu AM, Cucinelli F, Guido M, Pavone V, Caruso A. Preconceptional and gestational evaluation of insulin secretion in patients with polycystic ovary syndrome. Hum Reprod. 1996;11:2382–2386. [PubMed]
37. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698. [PubMed]
38. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr. 2001;138:38–44. [PubMed]
39. Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:226–229. [PubMed]
40. Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L. Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care. 2002;25:1217–1222. [PubMed]
41. Schachter M, Raziel, A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Human Reprod. 2003;18:721–727. [PubMed]
42. Kousta E, Cela E, Lawrence N, Penny A, Millauer B, White D, Wilson H, Robinson S, Johnston D, McCarthy M, Franks s. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 2000;53:501–507. [PubMed]
43. Galtier-Dereure F, Boegner C, Bringer J. Obesity and pregnancy: complications and cost. Am J Clin Nutr. 2000;71:1242S–1248S. [PubMed]
44. Scholl TO, Chen X. Insulin and the 'thrifty' woman: the influence of insulin during pregnancy on gestational weight gain and postpartum weight retention. Matern Child Health. 2002;6:255–261. [PubMed]
45. Turhan NO, Seckin NC, Aybar F, Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet. 2003;81:163–168. [PubMed]
46. Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, Katsikis I, Zournatzi V, Diamanti-Kandarakis E. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem. 2005;51:1691–1697. [PubMed]
47. Panidis D, Farmakiotis D, Koliakos G, Rousso D, Kourtis A, Katsikis I, Asteriadis C, Karayannis V, Diamanti-Kandarakis E. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod. 2005;20:2127–2132. [PubMed]
48. Jayapogopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2005;90:729–733. [PubMed]
49. Engelgau MM, Herman WH, Smith PJ, German RR, Aubert RE. The epidemiology of diabetes and pregnancy in the U.S., 1988. Diabetes Care. 1995;18:1029–1033. [PubMed]
50. Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, Fabregues F, Herrero J. Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update. 2005;11:375–390. [PubMed]
51. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–654. [PubMed]
52. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997;46:454–457. [PubMed]
53. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573–2579. [PubMed]
54. Working group report on high blood pressure in pregnancy . National High Blood Pressure Education Program. Bethesda: NIH; 2000. NIH publication 00-3029.
55. Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, Kalache K, Edwin S, Bujold E, Gomez R. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med. 2002;12:19–27. [PubMed]
56. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9:147–160. [PubMed]
57. Vural P. Nitric oxide/endothelin-1 in preeclampsia. Clin Chim Acta. 2002;317:65–70. [PubMed]
58. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med. 1999;222:222–235. [PubMed]
59. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001;285:1607–1612. [PubMed]
60. Solomon CG, Graves SW, Greene MF, Seely EW. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension. 1994;23:717–721. [PubMed]
61. Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet Gynecol. 2001;97:905–910. [PubMed]
62. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473–486. [PubMed]
63. Cales-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36–52. [PubMed]
64. Saftlas A, Wang W, Risch H, Woolson R, Hsu C, Bracken M. Pre-pregnancy body mass index and gestational weight gain as risk factors for preeclampsia and transient hypertension. Ann Epidemiol. 2000;10:475. [PubMed]
65. Sattar N, Clark P, Holmes A, Lean ME, Walker I, Greer IA. Antenatal waist circumference and hypertension risk. Obstet Gynecol. 2001;97:268–271. [PubMed]
66. Vambergue A, Nuttens MC, Goeusse P, Biausque S, Lepeut M, Fontaine P. Pregnancy induced hypertension in women with gestational carbohydrate intolerance: the diagest study. Eur J Obstet Gynecol Reprod Biol. 2002;102:31–35. [PubMed]
67. Kaaje R, Laivuori H, Laasko M, Tikkanen MJ, Ylikorkaia O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism. 1999;48:892–896. [PubMed]
68. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002;187:127–136. [PubMed]
69. Bruckdorfer KR. Antioxidants, lipoprotein oxidation, and arterial function. Lipids. 1996;31:S83–S85. [PubMed]
70. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001;276:25096–25100. [PubMed]
71. Visser W, Beckmann I, Knook MA, Wallenburg HC. Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-? release in preeclampsia. Acta Obstet Gynecol Scand. 2002;81:713–719. [PubMed]
72. Serin YS, Ozcelik B, Bapbou M, Kylyc H, Okur D, Erez R. Predictive value of tumor necrosis factor-α (TNF-αα in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2002;100:143–145. [PubMed]
73. Wolf M, Sandler L, Muniz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: prospective study. J Clin Endocrinol Metab. 2002;87:1563–1568. [PubMed]
74. Urman B, Sarac E, Dogan L, Gurgan T. Pregnancy in infertile PCOD patients: complications and outcome. J Reprod Med. 1997;42:501–505. [PubMed]
75. Baker PJ, Ramey ER, Ramwell PW. Androgen-mediated sex differences in cardiovascular responses in rats. Am J Physiol. 1978;235:H242–H246. [PubMed]
76. Wakasugi M, Noguchi T, Kazama YI, Kanemaru Y, Onaya T. The effects of sex hormones on the synthesis of prostacyclin (PGI2) by vascular tissues. Prostaglandins. 1989;37:401–409. [PubMed]

Articles from Hippokratia are provided here courtesy of Hippokratio General Hospital of Thessaloniki